# Semaglutide vs. tirzepatide: what single and dual action mean

Semaglutide targets GLP-1 receptors; tirzepatide targets GIP and GLP-1 receptors. How that difference fits into a treatment comparison.

Canonical: https://velri.co/blog/semaglutide-vs-tirzepatide-single-vs-dual-action-comparison
Publisher: Velri (https://velri.co/about)
Published: 2026-06-14
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Semaglutide activates GLP-1 receptors. Tirzepatide activates both GIP and GLP-1 receptors. “Dual action” describes that receptor activity; it does not mean the medicine is twice as effective or automatically the better choice. [1][2]

A meaningful comparison also includes the condition being treated, the exact product, side effects, other medicines and the person's medical history.

## How the signals differ

GLP-1 is involved in appetite and glucose regulation. Semaglutide's effects include reduced calorie intake and glucose-dependent effects on insulin and glucagon, hormones involved in blood glucose control. It also slows stomach emptying. [1]

Tirzepatide acts at GIP receptors as well as GLP-1 receptors. Its label describes effects on appetite, insulin secretion, glucagon and insulin sensitivity. Receptor activity explains how the medicine works; it is not a complete prediction of an individual's response. [2]

## Comparing outcomes requires comparable evidence

Results from separate trials can involve different populations, treatment durations and study designs. Those differences matter when reading a headline about weight change. A study average is not a forecast for one person.

The product studied also matters. Evidence from an FDA-approved product does not make a compounded preparation FDA-approved or interchangeable with it. FDA does not review compounded drugs for safety, effectiveness or quality before marketing. [3]

## Safety can decide the choice

Both medicines have contraindications and warnings, including specific thyroid-tumor history, serious allergic reactions and gastrointestinal risks. Pregnancy plans and other medicines must also be considered. Tirzepatide's labeling includes additional precautions about oral hormonal contraception. [1][2]

The decision therefore cannot be reduced to the number of receptors. A useful comparison explains why a particular option is being considered, what will be monitored and how problems will be handled.

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support